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ABSTRACT 
Tendon injuries are one of the most common orthopaedic problems in equine athletes but the 
avascularised nature, the hypocellularity and the low metabolic rate predispose tendons to 
slow healing with a high incidence of relapses.  
Nowadays, the improvement of regenerative therapies, whose aim is the restitution ad 
integrum of the tissue, has shown promising results with the application of stem cell-based 
therapies, growth factors (GFs) and low-level laser therapy (LLLT). 
The purpose of the present study was to develop a useful method to induce tenogenic 
differentiation of peripheral blood (PB)-derived mesenchymal stem cells (MSCs), through 
different combinations of basic Fibroblast growth factor (FGF), Transforming growth factor-
β3 (TGF), Insulin-like growth factor-1 (IGF), Epidermal growth factor (EGF) and a low-level 
laser irradiation (LLLT) in vitro. The relative expression of the following genes was evaluated 
by means of Real time-PCR: Early Growth Response Protein-1 (EGR1), Tenascin C (TNC) 
and Decorin (DCN).  
The results showed that the concomitant addition of FGF and TGF arrested cell proliferation 
and up-regulated the relative expression of EGR1 and DCN in both irradiated and non-
irradiated flasks, whereas only the combination FGF + TGF + LLLT was able to increase 
significantly TNC levels. We concluded that the supplementation of expansion medium with 
FGF and TGF is a useful method to induce MSCs differentiation towards the tenogenic fate. 
Overall, more in vitro and in vivo study needs to be performed, in order to better understand 
the correlation between MSCs and their niche. Indeed, the development of standard protocols 
of differentiation is recommended, in order to routinely apply induced-MSCs for the treatment 
of tendinopathies in horses.  
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RIASSUNTO 
Le lesioni tendinee rappresentano uno dei problemi ortopedici più frequenti nel cavallo 
sportivo. La scarsa vascolarizzazione e la bassa cellularità, accompagnata da un metabolismo 
strettamente anaerobico, predispongono il tessuto tendineo a una lenta guarigione e a 
un’elevata incidenza di ricadute, in seguito a traumi. 
Al giorno d’oggi, lo sviluppo di terapie rigenerative, il cui l’obiettivo principale è la 
restitution ad integrum del tessuto danneggiato, ha mostrato risultati incoraggianti soprattutto 
con l’utilizzo di terapie cellulari, fattori di crescita e tecnologia laser a bassa energia.  
Lo scopo del presente studio è quello di sviluppare un metodo efficace per indurre il 
differenziamento tenogenico, in vitro, di cellule staminali mesenchimali (MSCs) isolate dal 
sangue periferico (PB) di quattro cavalli adulti. Diverse combinazioni del fattore di crescita 
dei fibroblasti (FGF), fattore di crescita trasformante-β3 (TGF), fattore di crescita insulino-
simile-1 (IGF) e fattore di crescita dell’epidermide (EGF), sono state testate insieme alla 
tecnologia laser a bassa energia (LLLT). 
L’espressione relativa di geni coinvolti nello sviluppo tendineo è stata misurata tramite Real 
time-PCR. I geni che sono stati testati sono i seguenti: Early Growth Response Protein-1 
(EGR1), Tenascina C (TNC) e Decorina (DCN). 
 I risultati hanno mostrato che l’aggiunta concomitante dell’FGF con il TGF ha causato un 
arresto della proliferazione cellulare e un aumento dell’espressione relativa dell’EGR1 e della 
DCN, sia nelle colture che non sono state trattate con il LLLT, che in quelle trattate. Invece, 
solo la combinazione FGF + TGF + LLLT ha provocato un significativo aumento nel livello 
di espressione della TNC. 
Sulla base delle nostre osservazioni, possiamo dedurre che l’aggiunta di FGF e TGF nel 
medium di crescita è un metodo utile per incrementare il differenziamento tenogenico delle 
MSCs coltivate in vitro.  Tuttavia, ulteriori studi in questo campo si rendono necessari per 
poter raggiungere una migliore conoscenza delle interazioni che si realizzano tra le MSCs e la 
loro nicchia. Infatti, la possibilità di sviluppare dei protocolli di differenziamento standard 
sarebbe auspicabile per utilizzare al meglio le MSCs nel trattamento delle tendinopatie nel 
cavallo. 
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INTRODUCTION 
THE TENDON 
 
1. Tendon anatomy 
1.1 Macroscopic anatomy 
Tendons are anatomical structures interposed between muscles and bones. Tendons allow the 
transmission of forces generated by muscles contraction, resulting in the movement of joints 
and the maintenance of body posture. Moreover, tendons work as an energy- storing system 
that during the lengthening period of locomotion stores energy, which will be used as an 
elastic recoil during the propulsive phase. This property improves movement and reduces the 
workload of the muscles. Tendons can tolerate very high tensions undergoing minimal 
deformations, thus muscle contraction is optimized, with the minimum loss of energy and the 
maximum performance (Dyce et al. 2009). 
Healthy tendons are smooth, brilliant, and white in colour, with a fibro-elastic structure and a 
great resistance to mechanical loads. Tendons can be round cords, strap-like bands, or flatten 
ribbons. The shape and properties of tendons varies in function of the entire muscle-tendon 
complex behaviour. Muscles performing soft and delicate movements have long and thin 
tendons, instead, muscles creating powerful and resistant forces exert their action through 
short and thick cord- like tendons (Franchi et al. 2007; Sharma and Maffulli 2005). 
In those areas subjected to increased mechanical stress, tendons are covered by specialized 
sheaths such as, fibrous sheaths (or retinaculae), reflection pulleys, synovial sheaths, 
peritendon sheaths (or paratenon), and tendon bursae (Kannus, 2000). 
The histological knowledge of the tendon tissue is essential to understand its hierarchical 
structure and biomechanics.  
 
1.2 Microscopic anatomy 
A tendon is a tough band of dense regular connective tissue. It derives from mesenchyme, the 
embryonal connective tissue that takes origin from the mesoderm germ layer. Cells lie within 
an extracellular matrix (ECM), mainly composed by water (70%), fibres, proteoglycans (PGs) 
glycosaminoglycan (GAGs), and glycoproteins. ECM is a high-specialized dynamic structure, 
which not only offers a mechanical cell support, but mostly it regulates cell metabolism, 
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migration, proliferation, differentiation, apoptosis, and intercellular signalling. In turn, cells 
are responsible to secrete ECM components, thus conditioning ECM dynamics.  
 
1.2.1 Cells 
Tenoblasts and tenocytes constitute about 90-95% of the cellular elements of tendons. They 
are specialized fibroblast and fibrocytes that lie between collagen fibres. The remaining 5-
10% of cellular elements consists of chondrocytes, synovial cells, and vascular elements, 
including endothelial cells and smooth muscle cells. Tenoblasts are immature tendon cells, 
with numerous long and thin cytoplasmic processes that extend into the matrix. They are high 
metabolic cells engaged in the synthesis of all matrix components. As they mature, they 
flatten and become very elongated, transforming into tenocytes. 
Tenocytes are mature tendon cells with a low nucleus-to-cytoplasm ratio and longer and 
thinner cytoplasmic processes than tenoblasts. The cellularity in mature tendons is low and 
the metabolism is predominantly anaerobic. These characteristics are essential to maintain 
tendon tension and carry loads for long periods, but it predisposes the tendon to slow healing 
after injury (Kannus, 2000, Sharma and Maffulli 2005).  
 
1.2.2 ECM: Fibres 
Collagen type I is the main component of ECM, but also collagen type II and elastin are 
present. Collagen type II and elastin account for the 2% of the dry mass of the tendon, the 
former is particularly abundant at the osteo-tendinous junction, where high compressive loads 
are expressed and the latter is essential to give tendons the ability to cope with stretch and 
distension.  
Collagen type I represent the 95% of the dry mass of the tendon. Histologically, collagen 
fibres show a compact and parallel arrangement, hence, the classification as a dense regular 
connective tissue. Collagen is responsible for the high tendon tensile strength and it is 
arranged in hierarchical levels of increasing complexity.  
A collagen molecule is composed of three twisted polypeptide chains that form a right-handed 
triple helix, called tropocollagen. Soluble tropocollagen molecules align each other, head to 
tail, in overlapping rows, forming insoluble collagen fibrils.  
At the electronic microscopy, collagen fibrils have a diameter of 10 to 300 nm and show a 
characteristic horizontal streak of 67 nm intervals. The fibril strength is due to covalent bonds 
between collagen molecules of adjacent rows. Cross-links between collagen fibrils are 
essential to form collagen fibres.  
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A collagen fibre is the smallest tendon unit that can be tested mechanically and it is visible 
under light microscopy. (Dellmann and Eurell 2000; Patruno, 2010; Sharma and Maffulli 
2005). Collagen fibres are mainly oriented longitudinally, but fibres can also run transversally 
and horizontally, forming spirals and plaits. In general, there is a strong correlation between 
collagen orientation and functional requirements, in fact, the direction of fibres is always 
indicative of the prevalent tensile stress (Franchi et al. 2007). Fascicles of fibres then 
aggregate to form primary, secondary and tertiary bundles, which together constitute the 
tendon itself. Tendon fibres are bound together by the endotenon, a loose connective tissue 
layer that includes vessels and nerves. The epitenon is continuous with the endotenon and it 
surrounds the whole tendon.  
 
 
 
 
 
1.2.3 ECM: the ground substance  
The ground substance occupies the space between fibres and cells. It represents the main 
constituent of the tendon and it is composed predominantly by water (70%), proteoglycans 
(PGs), hyaluronic acid (HA) and glycoproteins. 
PGs are large macromolecules consisting of a core protein, to which many glycosaminoglycan 
(GAG) molecules are covalently attached. GAGs are short chains of polysaccharides made up 
of repeating disaccharide units, where one of the sugars is always a glucosamine. The main 
GAGs of ECM are chondroitin-sulphate, dermatan-sulphate, keratin-sulphate, heparin-
sulphate and hyaluronic acid (HA). GAGs are poli-ionic acid molecules, highly negative 
Figure 1: The hierarchical structure of the tendon (Kannus, 2000) 
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charged on the surface, because of the presence of sulphate, hydroxyl, and carboxyl groups, 
and thus highly hydrophilic. GAGs entrap water between fibres and cells forming a hydrated 
gel, which enables rapid diffusion of small water-soluble molecules and the migration of cells. 
(Dellmann, 2000; Patruno. 2010).  
HA is an extremely long and rigid GAG that differently from the others, it does not bind to a 
core protein, but proteoglycans indirectly bind to HA via special linker proteins to form a 
giant macromolecule. The biochemical characteristics of GAG molecules are of fundamental 
importance for the maintenance of ECM structure and function. 
 
 
Two groups of PGs have been demonstrated in the tendon: the small leucine- rich PGs 
(SLRPs) and the modular PGs (or hyalectans).  
SLRPs have a small core protein (~40 kDa) to which chondroitin-sulphate, dermatan-sulphate 
and keratan-sulphate molecules are attached. Decorin, biglycan, fibromodulin, and lumican 
belong to this group, they are able to bind to collagen fibrils, thus playing a key role in tendon 
collagen fibrillogenesis (Iozzo and Murdoch 1996; Yoon and Halper 2005). Collagen 
fibrillogenesis is a hierarchical process that depends on the unique structure and function of 
PGs. They promote the tip-to-tip collagen fibrils fusion and inhibits side-by-side interactions. 
Moreover, SLRPs interact with other ECM glycoproteins and growth factors, regulating cell 
proliferation (Graham et al. 2000).  
On the other hand, hyalectans have a big core protein (~160 kDa) with multiple domains, 
which interact with HA. By virtue of GAGs high negative charges, hyalectans provide to 
collagen fibrils the capacity to resist high compressive forces, associated with loading and 
movement. 
Figure 2: Schematic representation of a proteoglycan.  
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Decorin is the most abundant PG in tendon. Fibroblast, chondrocytes, endothelial cells and 
smooth muscle cells are all decorin-producing cells. The main function of decorin is to 
maintain collagen fibril structure, establishing inter fibrillary bridges, which contributes to 
keep the specific fibril parallel arrangement, thus preventing the lateral fusion (Iozzo et al. 
1999). Some studies have demonstrated the functional role of this PG by generating decorin-
deficient mice. Electron microscopic examination of decorin knockout mice skin showed that 
these animals presented skin fragility and a marked reduction in tensile strength. Compared 
with normal skin, the collagen network was loosely packed and collagen fibres had abnormal 
diameter (Danielson et al. 1997; Zhang et al. 2006). 
Several glycoproteins can be found in amorphous ground substance of tendon tissue such as, 
cartilage oligomeric matrix proteins (COMP), fibronectin, thrombospondin, and Tenascin-C 
(TNC). 
TNC has a very restricted expression in normal tissues, but it is up-regulated during 
embryogenesis and tissues particularly subjected to mechanical stress, as tendons. Those 
regions of tendons, particularly subjected to compressive loads, have a fibrocartilaginous 
structure and composition.  Cells can maintain their spherical shape and minimize their 
deformation, by virtue of their reduced adhesion to the ECM. TNC has been described as an 
anti-adhesive molecule that can decrease cell-matrix connections, allowing the free movement 
of cells within the adjacent collagen fibres (Mehr et al. 2000). To assess the importance of 
mechanical stress on TNC expression, a study was conducted in vivo at the osteo-tendinous 
junction (OTJ) of rat quadriceps muscles. After three weeks of cast immobilization, the 
immunoreactivity of TNC was almost completely absent at the OTJ, but once the application 
of an increased mechanical stress, the immunoreactivity of TNC reached the level of the 
healthy contralateral limb (Järvinen et al. 1999). Moreover, TNC expression is up regulated 
by several growth factors such as, basic fibroblast growth factor and transforming growth 
factor (Tucker et al. 1993). 
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2. Etiology of tendon lesions in sport horses 
2.1 Tendon injury 
Tendon anatomical characteristics are essential to confer the appropriate stiffness and 
elasticity that tendons need to perform their tasks. However, the not-vascularized nature, the 
hypo-cellularity, and the low metabolic rate of tenocytes result in slow healing and an 
inefficient tendon regenerative potential. 
Tendon injuries are one of the most common orthopaedic problems in equine athletes. Not 
only ageing and overloading, but also gender, morphology, foot conformation, ground 
conditioning, and training have been investigated as possible predisposing factors for 
tendinopathies. In thoroughbred horses, the prevalence of tendonitis is higher in the forelimbs 
and the superficial digital flexor tendon appears as the most involved structure, whereas, 
Standardbred racehorses show a higher incidence of desmitis at the suspensory ligament of 
the hindlimbs (Kasashima et al. 2004; Van den Belt et al. 1994).  
Tendon injuries may result from an acute trauma (e.g deep wounds, infections, tendon 
laceration or rupture) or chronic overuse, which is related to tendon overstrain. In fact, 
tendons are high compliant structures, which stays under moderate tension thanks to the 
characteristic waved configuration of collagen fibres, called “crimps”. Under physiological 
conditions, load causes less than 2% increase in tendon length, resulting in the flattening of 
the crimp pattern. In those circumstances, the tendon will be in the elastic phase or “toe” 
region. If the strain increases, but it remains below 4%, collagen fibres deform in a linear 
way, as a result of the sliding between collagen fibrils. This is called the visco-elastic phase 
(or linear region) and the tendon can return to its original length, when unloaded. Strains 
above 4% result in irreversible changes in the ground substance, which cause poor fibrillary 
organization and may lead to complete tendon rupture, if the strain reaches the 8-12%. It has 
been recorded that during gallop, the equine superficial digital flexor tendon (SDFT) works 
close to its limit with a narrow safety margin, thus predisposing equine athletes to develop 
tendon injuries especially in the flexor compartment (Stephens et al. 1989). 
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Figure 3: The curve shows the physiological relationship between stress and strain of a normal tendon 
(Riley 2004) 
 
2.2 Tendon healing 
The process of tendon healing represents an important paradigm for medical science. When 
tendons are damaged, they heal slowly, with the formation of scar tissue that is, almost 
always, mechanically inferior, and it cause a substantial loss in tendon original strength and 
elasticity.  
After injury, the first reaction is an inflammatory phase that last from several days up to two 
weeks. The extent of the inflammatory response determines the level of pain experienced, 
even if, it is not always correlated to the extent of the damage.  
Meanwhile, the repair phase starts and continue for several months. The repair phase is 
mainly characterized by angiogenesis and fibroplasia, with the deposition of random collagen 
type III fibres. As collagen type III tends to produce smaller and less organized fibrils, it will 
provide a structural (reparation) but not functional (regeneration) recovery after tendon lesion.  
Finally, there is the remodelling phase. It may last several years and it is characterized of 
collagen type III replacement by oriented collagen type I fibres. Although the extent to 
recover the original structure, the diameter and the cross-linking of collagen fibrils often 
remain inferior after healing. This mechanically inferior repair tissue produces a substantial 
loss in strength, elasticity, and a reduced athletic performance with high incidence of relapse 
(Sharma and Maffulli 2005; Spaas et al. 2012).  
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TREATMENT OF TENDON INJURIES IN EQUINE 
ATHLETES 
 
1. Conservative therapies 
Many medical and surgical therapies have been advocated in the treatment of equine tendon 
injuries. However, there is little objective evidence that they have consistent and long-term 
beneficial effects.  
The goals for the ideal treatment of tendinopathies are to decrease the local inflammation, 
reduce scar tissue formation, and improve tendon regeneration, in order to recover appropriate 
strength and elasticity.  
Box rest, ice application, and bandaging have been the cornerstones in the treatment of equine 
tendon injuries, during acute stages. These actions are important to limit the action of 
proteolytic enzymes on the remaining intact tendon matrix and they decrease the amount of 
exudation.  
In horses, it is possible to apply corrective shoeing, in order to progressively increase tendon 
strain and reduce the internal tension. However, this procedure may increase the damage in 
some circumstances, so its beneficial effect is controversial (Dowling et al. 2000).  
Controlled exercise and controlled passive mobilization are recommended in the management 
of acute tendon injuries, in fact, there are several reports supporting the benefits of 
physiotherapy on rehabilitation of musculoskeletal tissues. The duration of controlled exercise 
programmes is critical, and since that standard protocols of loading and movement, have not 
been identified yet, the amount work and time for the owner can exceed the results 
(Buckwalter, 1996; Takai et al. 1991).  
Besides controlled exercise is a valid method to improve tendon healing, pharmacological 
therapy is often necessary, especially during the acute phase of trauma.  
The use of corticosteroids appears to be beneficial especially during the first 24 hours’ post-
injury, whereas, the delayed use of corticosteroids is not believed to be helpful, as they will 
inhibit the fibroblastic response, which is necessary for tendon healing. Moreover, the period 
of rest should be further prolonged, because they mask the clinical signs of pain and this 
could be dangerous, if inadequately managed. On the other hand, the use of nonsteroidal anti-
inflammatory drugs is controversial and their application should be considered only to 
provide analgesia (Dowling et al. 2000). 
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The intra-lesional or peri-tendinous injection of HA has yielded conflicting results and it does 
not appear to show significant benefits.  
The use of polyshulphated glycosaminoglycans and beta-aminoproprionitrile fumarate is 
potentially helpful, during the acute stages of tendinopathies. The beta-aminoproprionitrile 
fumarate is a toxic agent, found in the seeds of the plant Lanthyrus odoratus. It prevents the 
excessive fibrils cross-linking in the early stages of tendon repair, promoting the linearization 
of collagen fibres. However, it requires a strict and careful controlled exercises, and long-term 
data shows that only the 50% of treated horses return to their maximal athletic activity 
(Dowling et al. 2000). 
Surgical therapies are invasive, expensive and sometimes dangerous, for all complications 
related to general anaesthesia and operation. The most commonly used techniques include: 
percutaneous tendon splitting, accessory ligament desmotomy, digital anular ligament 
desmotomy and the use of carbon fibres implants. Counter irritation was one of the most 
common methods employed in the horse for the treatment of chronic musculoskeletal injuries. 
By the time, it was demonstrated that firing has no benefits in tendon healing and it increase 
the incidence of peritendinous adhesions. It is now considered an inappropriate treatment, 
even if, there are still many supporters of it (Dowling et al. 2000, Spaas et al. 2012). 
 
 
2. Innovative therapies  
Since conservative therapies usually involve long period, with no significant improvement in 
tendon functionality, the use of regenerative therapies has been encouraged.  
Regenerative therapy is an innovative medical field, whose aim is to stimulate the body’s own 
repair mechanisms, in order to restore complete structure and function of damaged tissues and 
organs.  
The broad field of regenerative medicine covers a variety of research areas, including stem 
cell therapies, growth factors, platelet-rich plasma, tissue engineering and low level laser 
irradiation.  
 
2.1 Cell-based therapies 
The limited ability of tendon to self-repair had encouraged researchers to develop cell-based 
strategies, in order to explore the natural endogenous system of tissue regeneration. Cell-
based therapies are defined as the process of introducing new cells, in order to treat a disease 
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or regenerate damaged tissue, and it includes pluripotent stem cells, multipotent stem cells, 
and mature functional cells.  
 
2.1.1 Definition of stem cells (SCs) 
SCs are unique cells that have the capacity for self-renewal and to give rise different cell 
lineages that form mature adult tissues (Donovan and Gearhart 2001). SCs are able to form 
identical daughter cells, when performing symmetrical divisions, or more differentiated 
daughter cells, if asymmetrical division occurs (Blanpain and Fuchs 2009). Thanks to their 
proliferative nature, SCs are able to repopulate entire organs and regenerate tissues that 
normally heal with the formation of scar tissue, thus losing their original properties.  
In order to better understand SCs origin and characteristics, a brief revision on embryology is 
advisable. After the fertilization of the oocyte, symmetrical divisions produce totipotent SCs, 
which are able to originate the embryo itself and the extra-embryonal tissues. Then, 
symmetrical and asymmetrical divisions form a blastocyst consisting of: i) the trophoblast and 
ii) an inner cell mass. The inner cell mass contains pluripotent embryonic SCs, which are able 
to proliferate, indefinitely, and differentiate into a wide variety of cell types, representative of 
the three embryonal germ layers: endoderm, mesoderm and ectoderm (De Vos et al. 2009; 
Donovan and Gearhart 2001; Li et al. 2006; Paris and Stout 2010). After gastrulation, 
multipotent stem cells develop from symmetrical and asymmetrical divisions. These cells 
have more specific tasks and a reduced plasticity than the pluripotent embryonic SCs, indeed, 
they are also called adult stem cells. The main function of the multipotent SCs is to regulate 
the inner body homeostasis, in order to replace those cells, which are damaged or death 
because of senescence or injury.   
 
 
 
 
 
 
 
 
 
 
Figure 4: Stem cell hierarchy (Spencer et al. 2011)  
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2.1.2 Mesenchymal stem cells (MSCs) 
Multipotent stem cells, which are able to differentiate into cells of the mesoderm germ layer, 
are called mesenchymal stem cells (MSCs). Since their discovery, their potential use in 
regenerative medicine has been studied with increasing interest. Actually, the use of adult 
multipotent MSCs is encouraged, because they do not show the collateral effect to form 
teratoma in vivo, differently from pluripotent embryonal SCs (Fong et al. 2010). In fact, 
MSCs do not elicit hypersensitivity reactions and they also have immunomodulatory effects 
(Ringdén et al. 2006). MSCs inhibit T-lymphocytes proliferation (Di Nicola et al. 2002), B-
lymphocytes differentiation, immunoglobulin production (Corcione et al. 2006), macrophages 
activity (Ortiz et al. 2007), and dendritic cells maturation (Djouad et al. 2007). In the horse, 
the opportunity to use allogenic stem cells, without adverse reaction, has been described in 
several studies (Broeckx et al. 2014; Carrade et al. 2011a, Carrade et al. 2011b). MSCs have a 
fibroblast-like shape and they can be isolated from different sources such as, bone marrow 
(BM), adipose tissue, umbilical cord, umbilical cord blood, amniotic fluid, gingiva, 
periodontal ligament, and peripheral blood (PB). MSCs exhibit the ability to be committed 
into the cell lineages of the mesoderm layer and several studies have successfully proven their 
osteogenic, adipogenic, chondrogenic (Barberini et al. 2014; Spaas et al. 2013), myogenic 
(Martinello et al. 2010), and tenogenic differentiative potential (Kraus et al. 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 5: Schematic representation of differentiative potential of MSCs (Caplan, 2007) 
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In equine medicine, current MSCs therapies mainly use BM and PB-derived MSCs. Since the 
sample of BM-derived MSCs can be painful, risky and it requires a certain degree of 
competence, the use of PB-derived MSCs allows several advantages. In fact, the blood 
samples can be easily taken in a sterile manner, at the time of injury, and they provide a 
rapidly and a high accessible source of MSCs (Spaas et al. 2013). 
Thanks to their great characteristics, PB-derived MSCs represent an innovative field of 
research, in the area of regenerative therapies for the treatment of musculoskeletal pathologies 
in horses.  
 
2.1.3 Cluster of differentiation (CD) 
The cluster of differentiation (CD) represents a system to identify molecules, mainly 
glycoproteins, which are expressed on the surface of the cell membrane. The CD is a method 
of cellular marking that usually is performed by means of flow cytometry. It permits cellular 
identification on the base of its membrane molecular expression, indeed, more than one CD 
marker is usually required, in order to identify a cell type.  
In 2006, the International Society for Cellular Therapy (ISCT) has carefully determined the 
qualities that human cells must possess in order to be defined as MSCs. Human MSCs have to 
be positive for typical stem cell markers such as, CD73, CD90, CD105, and negative for adult 
blood cell markers like CD11b, CD14, CD34, CD45, CD79α, or CD19, MCH II and 
monocyte/macrophage (Mo/Ma) markers (Dominici et al. 2006). 
No such guidelines have been described for equine MSCs, but several studies have been 
performed, in order to achieve a better characterisation of equine MSCs. In fact, considering 
the particular case of PB-derived MSCs, they were shown to be positive for CD13, CD29, 
CD44, CD51, CD90, CD105, CD117 and negative for CD34, CD45, CD79α, MCH II and 
Mo/Ma (Dhar et al. 2012; Martinello et al. 2010; Spaas et al. 2013).  
 
2.1.4 The MSCs niche 
The stem cell niche is defined as the micro-environment where SCs reside. It constitutes a 
basic unit of tissue physiology, it integrates signals and mediates a balanced response of stem 
cells with the needs of organism (Scadden 2006). This means that the specific interactions 
between MSCs and their micro-environment, determines whether or not, a SC remains 
quiescent, starts to proliferate, or differentiate into an adult cell (Kuhn and Tuan 2010). The 
niche is both physical and biological that is, factors such as, temperature, oxygen level, 
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relative humidity, surrounding cells, ECM, growth factors, and cytokines influence MSCs 
behaviour.  
The understanding of that specific interactions, which exist between the niche and the residing 
MSCs, is fundamental to obtain the manipulation of the niche in vitro, in order to guide the 
further development of MSCs. 
It has been described that MSCs can migrate at the injury site and release leukocyte 
chemokines important to attract immune cells and local MSCs, in order to heal the damaged 
tissue (Shi et al. 2010). The pro-inflammatory cytokines, which are present at the site of 
injury, influence MSCs behaviour, by increasing their proliferation and maintaining them at 
the undifferentiated state (Pricola et al. 2009).   
Although various clinical applications of MSCs has been described, the exact modus operandi 
of SCs remains a question and their therapeutic effects are not well understood and 
characterized. It is generally accepted that the positive effects of SC therapy are due to the 
products they secrete, which enhance the metabolic function of other cells (Yang et al. 2013), 
even if, other studies reported a stable and uniform integration of MSCs in the injured site, 
indicating a sort of structural support (Martinello et al. 2012). 
The possibility to understand, which factors alter MSCs behaviour in vitro, could be of vital 
importance to increase the efficacy of MSCs in vivo, in order to obtain the wanted 
commitment, improve the effectiveness of cell-based therapies, and increase the positive 
outcome of injured patients.  
 
2.1.5 Use of MSCs for the treatment of equine tendinopathies 
Once that the great in vitro potential of MSC has been discovered, the interest for regenerative 
medicine and in particular for cell-based therapy, increased exponentially. In horses, several 
in vivo studies have been performed, in order to better understand MSCs behaviour and 
effects after clinical application. The treatment of orthopaedic problems, in this specie, is one 
of the hottest topics, because of the large employ of these animals for sport competitions, their 
economic value, the high incidence of orthopaedic injuries and relapses.  
The use of MSCs for the treatment of tendon injuries showed cheering results, compared to 
non-regenerative approaches, in several in vivo studies. The application of tenogenic induced 
MSCs for the treatment of desmitis of the equine accessory ligament, outcomes clinical and 
ultrasonographical positive results, with an improvement of about 80% on the ultrasound 
image, already 6 weeks after the intralesional injection (Beerts et al. 2013). SC therapy was 
applied also in a 13-year-old Belgian warmblood mare that showed lameness and swelling on 
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the right front leg. On ultrasound examination, heterogenic regions were noted in the mid-
region of the suspensory ligament. Five weeks after the intralesional injection of SCs, the 
swelling had disappeared and the horse do not showed more signs of lameness. Moreover, the 
lesion was filled with tendon tissue, even if, at the edges was still noticeable some 
heterogeneity that disappeared after nine weeks. At six months’ post-injection, this horse 
reached the original level of competition in show jumping, without more relapses (Spaas et al. 
2011). Another case report demonstrated a positive evolution of proximal suspensory 
ligament desmitis, after the treatment with allogenic tenogenic-induced MSCs. The horse was 
submitted to two intralesional injections of tenogenic-induced MSCs and after 32 weeks, it 
went back to the previous performance level, with a total filling of the lesion on ultrasound 
(Vandenberghe et al. 2015). Smith et al. (2013) conducted a study on twelve career-ending 
horses, with naturally occurred SDFT injuries. The horses were treated with autologous BM-
derived MSCs and after 6 months’, the histological examination of tendons displayed an 
enhanced normalization in morphological and compositional parameters, than the untreated 
tendons (Smith et al.  2013). At last, the combined use of MSCs and platelet-rich plasma 
(PRP) was tested on experimentally injured deep digital flexor tendon (DDFT) of sheep. The 
results highlighted the predominant effect of MSCs on tendon healing, with enhanced tissue 
remodelling and improved structural organization, whereas, the combination of both 
treatments did not produce synergistic effects (Martinello et al. 2012).  
All these studies represent only a little example of the great potential of MSCs. For all the 
aforementioned reasons, the improvement of regenerative medicine represents the key for the 
treatment of all that pathologies, which naturally do not heal with a restitution ad integrum of 
the tissue. Of course, more in vitro and in vivo studies must be performed, in order to better 
understand the correlation between MSCs and their niche, and be able to use regenerative 
therapies, routinely, for the treatment of tendinopathies in horses.  
 
2.2 Growth factors (GFs) 
The improvement of knowledge about tendon development and healing, has resulted in the 
investigation of various GFs as therapeutic agents in musculoskeletal healing. In fact, it is 
overall accepted that environmental factors are of vital important to control stem cell activity.  
GFs are signalling peptides with various biological roles, including cell proliferation, 
differentiation, migration, and adhesion. They represent one of the most important molecules 
involved in healing processes, therefore, they can influence stem cells behaviour and 
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differentiation, with vital consequences for regenerative therapies progress. (Dahlgren et al. 
2005). 
Several growth factors have been investigated as playing a key role in tendon healing such as, 
basic fibroblast growth factor, transforming growth factor-beta, insulin-like growth factor-1, 
epidermal growth factor, vascular endothelial growth factor and platelet-derived growth factor 
(Tsubone et al. 2004). They can be produced by both intrinsic or extrinsic cells, they often 
have dose-dependent effects and work in synergy with other signalling molecules. In fact, a 
study demonstrated that the introduction of a single GF can modulate the expression of 
multiple GFs genes (Tang et al. 2014).  
 
2.2.1 Basic fibroblast growth factor (FGF) 
FGF is a signalling molecule required in the early stages of differentiation and an essential 
mediator for self-renewal in human stem cells. 
Several studies have demonstrated the involvement of FGF in tendon healing by regulating 
cell growth and differentiation. In this regard, Chang et al. (1998) showed that tendons 
subjected to transection and repair, exhibited an increased mRNA expression of FGF, in both 
resident and migrating cells. FGF is able to stimulate cell proliferation and induce cell 
differentiation towards the tenogenic fate via the activation of the mitogen-activated protein 
kinase (MAPK), which includes ERK1 and ERK2 signalling pathways, both involved in 
tenogenic differentiation (Cai et al. 2013; Reed et al. 2014). In fact, the supplementation of 
FGF can increase the mRNA expression of TNC, collagen type I, collagen type III, 
fibronectin and alpha-smooth muscle actin. The microscopic evaluation of MSCs cultured 
with FGF supplementation resulted in a homogenous and dense ECM, with fibroblast-like and 
spindle shaped cells, supporting the key role of this GFs in tendon commitment (Chan et al. 
2000; Gonçalves et al. 2013; Hankemeier et al. 2005; Molloy, 2003; Reed et al. 2014).  
 
2.2.2 Transforming growth factor-β3 (TGF) 
TGF is a well-known cytokine that regulates various cellular processes, including cell 
proliferation, differentiation, apoptosis, plasticity and migration (Zhao and Chen 2014).  
TGF plays a key role during all phases of tendon healing, but its mRNA expression increases 
especially during the inflammatory phase (Fu et al. 2002; Molloy et al. 2003).  
The supplementation of TGF in MSCs cultures in vitro is able to induce tenogenic 
differentiation by up-regulating the mRNA expression of TNC, Collagen type I, type III, 
COMP, tenomodulin and thrombospondin, which are all ECM components of tendon tissue 
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(Barsby et al. 2014; Dowling et al. 2000). The increased synthesis of this constituents is 
correlated with a concomitant decrease in cell number, via the cyclin-dependent kinase 
inhibitors, supporting the key role of TGF for tendon commitment (Klein et al. 2002; Molloy 
et al. 2003). 
 
2.2.3 Insulin-like growth factor-1 (IGF) 
IGF-1 is an important mediator in all phases of wound healing and it ensures a rapid response 
to injury especially during the inflammatory and repair stages. IGF is a versatile and 
widespread molecule with numerous tasks in tendon healing. It enhances tendon repair, 
promotes cell proliferation, and increases collagen type I and fibronectin synthesis. (Dahlgren 
2005; Dowling et al. 2000; Hansen et al. 2013; Molloy 2003). 
 
2.2.4 Epidermal growth factor (EGF) 
EGF is a powerful mitogen. It participates in MSCs, fibroblast proliferation, and it is also 
involved in the initial phase of tendon healing. (Gonçalves et al. 2013). An in vitro study 
showed that EGF had a stimulatory effect on tenoblast migration and this might enhance 
tendon repair, by delivering immature cells at the site of injury (Jann et al. 1999). 
 
2.2.5 Platelet-rich plasma (PRP) 
The use of a single GF often may not be sufficient to improve the quality of tendon healing. 
Actually, one of the most explored GF-based therapy in equine medicine is PRP, an 
autologous concentrate of platelets in a small volume of plasma. PRP is used as a source of 
GFs, in fact, platelets α-granules are rich in GFs such as, TGFβ, IGF, platelet-derived growth 
factor (PDGF) and vascular endothelial growth factor (VEGF). These GFs may play a central 
role in tendon healing, reducing inflammation and scar tissue production. There are many 
experimental evidences that PRP can enhance angiogenesis, recruitment, proliferation and 
differentiation of cells involved in tissue regeneration (Anitua et al. 2015, Martinello et al. 
2012). The use of PRP in vitro, resulted in increased cell proliferation and collagen 
deposition. In collagenase-induced SDFT lesions, studies showed successful results in the 
treatment of both acute and chronic injuries, with histological increase of fibroblastic activity 
and better organization of collagen fibres (Maia et al. 2009; Spaas et al. 2012). PRP was 
applied in vivo also in combination with MSCs, but the results are controversial. At present, 
the clinical efficacy of PRP is still debated because too many factors can influence the result 
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such as, the seriousness of the injury, the healing phase, the PRP preparation method, and of 
course the individual (Abate et al. 2012). 
 
2.3 Low-level laser therapy (LLLT) 
The clinical application of low levels of visible light for reducing pain, inflammation, and 
promoting tissue healing, has been known for almost forty years, since the invention of lasers. 
Despite many reports of positive outcomes, the clinical use of LLLT remains controversial. 
This is mainly due of two reasons: first, the biochemical mechanisms underlying the laser 
positive effects are incompletely understood, second the opportunity to change several 
parameters such as, wavelength, fluency, power density, and timing, enlarges the possibility 
to work in several different conditions and thus, to obtain a wide range of results.  
 It has been found that exists an optimal dose of light for each tissue and purpose, in fact 
doses lower, or more significantly higher, than this optimal value have a diminished 
therapeutic effect.  
 
2.3.1 Physical mechanism: 
According to quantum mechanical theory, light energy is composed of photons, or discrete 
packets of electromagnetic energy. The energy of an individual photon depends only on its 
wavelength, therefore the energy of a “light-dose” depends only on the number of photons 
and on their wavelength.  
Photons delivered into living tissues can either be absorbed, or scattered. Scattered photons 
will escape from the tissue, whereas, the energy coming from absorbed photons will be 
conserved and internally converted into heat, fluorescence, or it can activate a broadly number 
of biochemical processes (Hamblin, 2006). 
 
2.3.2 Biochemical mechanism: 
The first law of photochemistry states that light must be absorbed, so that photochemistry can 
occur. This is a simple concept, but it is the basis for performing photo-biological experiments 
correctly. The optical properties of tissues are of fundamental importance because, both the 
absorption and the scattering of the light, are wavelength dependent. There is an ideal “optical 
window”, between 600 and 1200 nm of wavelength, in which laser radiations are absorbed by 
more tissue elements and this increases the opportunity for light to be absorbed (Hamblin, 
2006). 
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It was suggested that the components of the respiratory chain were responsible for light 
absorption. Actually, it is known that cytochrome c oxidase is the primary photoacceptor, in 
fact, it absorbs light of wavelengths between 630 nm and 900 nm. The increased amount of 
energy in the respiratory chain leads to an acceleration of electron transfer, and thus ATP 
production. Moreover, changes in the redox state induce the activation of numerous 
intracellular signalling pathways and of course, cells at different state of development have 
distinct redox states (Hamblin, 2006). 
 
2.3.3 In vitro and in vivo application of LLLT: 
The effects of LLLT can vary considerably between cells, but in general, in vitro studies 
showed that the response after LLLT is an increased cell metabolism, proliferation, and 
synthesis of proteins. Sperandio et al. (2015) showed an enhanced in vitro proliferation and a 
faster in vivo maturation of human keratinocytes irradiated with a wavelength of 660 nm and 
3, 6 and 12 J/cm2 energy laser densities. Similar results have been reported in another study, 
in which laser energy densities of 5J/cm2 were applied on wounded cells. The results showed 
an increased cell migration across the wound margin, fibroblast proliferation, and cell 
viability. Instead, higher doses of 10 and 16J/cm2 energy densities, were characterized by a 
decrease in cell vitality and proliferation, because of a significant damage of the cell 
membrane and DNA (Hawkins and Abrahamse 2006). Several studies support the hypothesis 
that 5J/cm2 is the optimal fluence to apply in vitro, in order to enhance cell proliferation and 
differentiation. In fact, it has been shown that an energy density of 5J/cm2 dramatically 
enhances MSCs proliferation and differentiation, especially when cells are cultured in 
appropriate inducing medium (Hou et al. 2008). Similar results were obtained by de Villiers et 
al. (2011) who exposed human adipose tissue-derived MSCs to a 636 nm diode laser and a 
fluence of 5J/cm2. Cell were induced to differentiate into smooth muscle cells by using 
retinoic acid. The results showed a significant increase of cell proliferation and viability after 
72h post-irradiation, whereas a longer period of time (14 days) was necessary to induce MSCs 
differentiation.  
Moreover, a recent study was performed on tenocytes in vitro. The application of LLLT (904 
nm wavelength and 1J/cm2 energy density) revealed a significant increase in cell proliferation 
and an up-regulation of collagen type I and TGF-β1 expression (Chen et al. 2015).  
The use of LLLT has been proposed also in physical medicine, in order to accelerate recovery 
after musculoskeletal injuries and reduce the inflammatory phase. Studies showed that the 
application of LLLT on muscle, bone, and tendon cells can increase not only cell 
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proliferation, but also cell differentiation. The opportunity to increase cell differentiation, by 
the combined use of stem cell-based therapies and LLLT, can be of great help for the 
treatment of orthopaedic injuries, which have a reduced regenerative capacity such as, 
tendinopathies.  
Since, in tendon injuries there is an increased concentration of pro-inflammatory cytokines, a 
study was conducted on forty-two male rats with collagenase-induced tendinitis. A LLLT was 
performed (wavelength of 780 nm; energy density of 7,7J/cm2; 75s exposure) and the results 
showed a decrease in IL-6, COX-2, TGF-β, and TNF-α expression, in both acute and chronic 
inflammatory phases. These results suggest the therapeutical effect of LLLT and encourage 
the application of this protocol, for the management of pain during tendinopathies (Pires et al. 
2011).  
An interesting in vivo study was conducted on collagenase-induced tendinitis of the DDFT in 
sheep. The sheep was chosen as a model, since it shares a lot of similarities with the 
connective tissue of humans and equines flexor tendons. Sheep were divided into two groups 
and treated for 7 days with LLLT doses of 5J/cm2 and 2,5J/cm2 respectively. Clinical and 
histological evaluations demonstrated that the dose of 2,5J/cm2 resulted in better improved of 
anti-inflammatory effects, significant decrease in fibroblasts number, low vascularity, better 
collagen fibre-alignment, and ECM organization than the 5J/cm2 group (Iacopetti et al. 2015). 
This study further confirms that exists an optimal dose for each tissue and the application of 
lower, or higher doses, can produce null or even dangerous effects.  
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GENERAL AIM OF THE STUDY 
The aim of the present study was to investigate the in vitro combined effect of growth factors 
and a low-level laser irradiation on peripheral blood (PB)-derived mesenchymal stem cells 
(MSCs). 
Tendon injuries are one of the most common orthopaedic problems in equine athletes and 
they often compromise the return at the same performance level. Tendinopathies may result 
from an acute trauma or more often from chronic overstrain. In both cases, the tendon will 
heal with the formation of scar tissue, which results in a higher content of collagen type III, 
reduced strength and elasticity. 
The restitution ad integrum of the damaged tissue is the goal for regenerative therapies, which 
includes stem cell based therapies, the use of growth factors and low-level laser therapy.  
Moreover, a more recent approach is the tenogenic induction of MSCs before their clinical 
use, in order to increase the regenerative potential of MSCs.   
This project focussed on the investigation of the in vitro combined effect of basic fibroblast 
growth factor, transforming growth factor-β3, insulin growth factor-1, epidermal growth 
factor, and low-level laser irradiation on equine PB-derived MSCs. Different combinations of 
these growth factors were tested, with and without the low-level laser irradiation, in order to 
evaluate the best culture conditions for tenogenic differentiation of MSCs. At the end of the 
culture, the relative expression of Early Growth Response Protein-1, Tenascin C and Decorin 
was measured by real-time PCR, since they are all crucial genes involved in tenogenesis and 
tendon healing. 
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MATHERIALS AND METHODS 
 
1. Animal selection and management 
The animals, chosen for the study, were four adult trotter mares of five, six and seven years 
old. The mares were coming from the same stable and were placed in a big paddock at 
EquiTom, Equine Clinic, in Belgium. The horses were healthy, vaccinated, and de-wormed. 
They were fed twice a day with hay, once with concentrate, and water always ad-libitum. The 
four donor horses were left in the paddock for one week, without stress or manipulations, in 
order to let them get used of the new environment. 
 
 
 
 
 
Figure 1: The horses of the study, stabled at EquiTom Equine Clinic, in Belgium. 
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2. Isolation of the putative PB-derived MSCs 
After one week of horses’ acclimatization, twenty ml of blood were collected, from the 
external jugular vein, of each animal. The blood was taken in a sterile manner and placed into 
five sterile EDTA (Ethylene-diamine-tetraacetic acid) tubes of 4 ml. The blood samples were 
transported to the GST laboratory, at room temperature (RT), within four hours of sampling. 
Then, the blood was placed into two sterile 15 ml tubes and centrifuged at RT for 20 min and 
1000g. The high G-force is important to separate the buffy coat, which contains white blood 
cells and stem cells. 
The buffy coat was collected, diluted 1:2 in a phosphate buffered saline (PBS) solution, and 
gently laid on an equal amount of Percoll gradient (density 1.080 g/ml; GE Healtcare). Percoll 
is a colloidal silica particles suspension, which lets the higher isolation of stem cells from red 
blood cells, platelets, and plasma.  
The solution with Percoll and buffy coat was centrifuged for 15 min at RT and 600g. After 
this process, it was possible to distinguish 4 phases: the upper containing plasma, an opaque 
interphase containing MSCs and mononuclear white blood cells, the Percoll solution, and at 
the bottom the pellet, consisting of red blood cells, granulocytes, and platelets. 
The interphase containing the putative MSCs was collected and, in order to obtain a better 
isolation of cells from plasma, it was diluted 1:2 with PBS and centrifuged for 10 min at 
200g. This passage was repeated 3 times. The upper part was thrown away, while the 
sediment re-suspended in an equal amount of PBS.  
At last, the pellet was suspended in 12 ml of expansion medium prepared as follow: 
Dulbecco’s Modified Eagle Medium (DMEM, Euroclone ECM0728L), 20% calf serum (FCS, 
Euroclone ECS0180L), 1% antibiotics/antimycotics (Euroclone ECB3001D) and 10-11 M 
dexamethasone (Sigma Aldrich).  
 
 
3. Culture of the PB-derived MSCs 
The putative MSCs were seeded in T75 flasks with the expansion medium previously 
described. The medium was refreshed twice a week and cells cultured at 37 °C with 5% of 
CO2.  
At 70% of confluency, the flask was changed for the next passage. First, the old medium was 
removed and the flask washed with 10 ml of PBS. In order to detach the cells from the flask, 
6 ml of 0,25% Trypsin EDTA (Euroclone ECB3051D) were added and the flask was 
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incubated for a maximum of three minutes at 37 °C and 5% of CO2. The incubation is 
important because trypsin is a protease and it needs culture conditions to perform its tasks.  
Once that the cells were floating, 6 ml of expansion medium were added, in order to stop the 
action of trypsin by calf serum anti-proteases.  
The suspension was centrifuged for 8 minutes at 300g. The supernatant was removed and the 
pellet, containing the cultured MSCs, re-suspended in 12 ml of new and fresh medium.  
Finally, the cells were seeded in a new T75 flask and further cultured for the next passages. 
This procedure was repeated for each passage, from 0 to 10 (P0 →10).   
The expansion medium was supplemented with dexamethasone only at P0, in order to enhance 
glucose metabolism and help the proliferation of cells at the beginning.  
 
 
4. Population doubling time (PDT) 
At each passage, cell count was performed, in order to seed the same amount of cells and 
calculate population doubling time (PDT).  
PDT was calculated from P1 to P10 with the following formula (Hoynowski et al. 2007):  
 
 PDT= cell culture time (T)/cell doubling time (CDT)  
 
T was expressed as days from Ni to Nf, where Ni is the initial number of cells and Nf is the 
final number of cells, for each passage. CDT was obtained with the following formula:  
 
 CDT= ln(Ni/ Nf)/ln(2)  
 
 
5. Flow cytometry 
In order to achieve immunophenotypic characterization of undifferentiated PB-derived MSCs, 
the expression of several MSCs markers was evaluated by flow cytometry.  
At passage P5 and P10, the putative PB-derived MSCs, cultured in expansion medium, were 
sent to GST-ANACURA laboratory and tested for stem cell Cluster of Differentiation (CD) 
markers CD29, CD44, CD90, and for adult blood cell (negative) markers CD45, major 
histocompatibility complex type II (MHC II), and monocyte/macrophage marker (Mo/Ma). 
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Per series, 2x105 cells were labelled using the following panel of primary antibodies: CD29-
APC (TS2/16, Biolegend), CD44-FITC (CVS18, AbD Serotec), CD90 (DH24A, VMRD), 
CD45-PeCy5.5 (F10-89-4, AbD Serotec), MCHII-PE (CVS20, AbD Serotec), and Mo/Ma 
marker-Alexa 488 (MAC387, AbD Serotec).  
In general, cells were incubated for 15 min, in ice and dark with primary antibodies and then 
washed twice in DMEM. A second incubation, in ice and dark for 15 min, was perfomed only 
on CD90 positive cells, in order to label them with fluorocrome PE-linked antibody IgG1-PE-
Cy7 (Biolegend).  
Control isotypes were run for each marker, in order to define the threshold at 0-1% of positive 
signals. The samples were analysed on a FACSCanto II (BD Biosciences) instrument, 
equipped with a 488 nm solid state and a 633 nm HeNe laser. The optimal settings for the 
MSC were determined by Compbeads Plus beads. The performance of the flow cytometer was 
checked on a daily basis by Cytometer Setup & Tracking beads (BD Biosciences). A 
minimum of 10.000 MSCs were used for flow cytometric evaluation and the data were 
analyzed with the FacsDiva software.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: The image shows FACSCanto II (BD Bioscences), the instrument used to perform flow 
cytometry. 
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6.  Addition of growth factors (GFs) 
In order to evaluate the effects of medium composition on MSCs tenogenic differentiation, 
several combinations of basic fibroblast growth factor (FGF), transforming growth factor-β3 
(TGF), insulin-like growth factor-1 (IGF) and epidermal growth factor (EGF) were tested.  
When PB-derived MSCs reached P5, cells were collected, suspended in 6 ml of expansion 
medium, and seeded in T25 flasks, with a concentration of 1500 cell/cm2. 
The expansion medium was supplemented with the following combinations of GFs (Sigma-
Aldrich): FGF, FGF + TGF, FGF + IGF, and FGF +EGF. All these GFs were added at the 
concentration of 10 ng/ml. 
Since expansion medium (Exp) served as negative control, five culture conditions were tested 
for each horse, in duplicate, for a total of forty T25 flasks (Table 1). 
Cells were cultured in T25 flasks for five days at 37 °C and 5% CO2.  The medium was 
refreshed at day three.  
 
     
Exp FGF FGF + TGF FGF + IGF FGF + EGF 
 
Table 1: Expansion medium was supplemented with several combinations of growth factors, 
obtaining five culture conditions, which were tested in duplicate, for each horse. 
 
 
7. Low-level laser technology (LLLT) 
The PB-derived MSCs, cultured in supplemented media as previously described, were divided 
in two equal groups of twenty T25 flasks for each, in order to test, in one group (Group 2), the 
combined effect of GFs and a low-level laser irradiation (LLLT) on MSCs proliferation, 
viability and tenogenic differentiation (Table 2). 
The first irradiation was performed 24 hours after seeding. A dose of 5J/cm2 was applied 
daily, for 2 min by the same operator, with continuous and pulsed emissions emitted by a 
single handpiece (ASAlaser, M6, handpiece). The radiation was produced by an InGa(Al)As 
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diode laser with 2 cm spot size. The wavelength of continuous and pulsed emission was 660 
nm, and 905 nm, respectively.  
The PB-derived MSCs, cultured in expansion and supplemented media, were irradiated from 
day two to five, after the seeding. 
 
 
 
                                                 Group 1: Non-irradiated flasks 
     
Exp FGF FGF + TGF FGF + IGF FGF + EGF 
          
                                                     Group 2: Irradiated flasks 
     
Exp + LLLT FGF + LLLT FGF + TGF + LLLT FGF + IGF + LLLT FGF + EGF + LLLT 
 
Table 2: Schematic representation of the treatments. Five culture conditions were tested for each 
horse, in duplicate, for a total of forty T25 flasks. The flasks were divided in two equal groups and one 
group was submitted to LLLT. 
Figure 3: The picture shows the instrument used to irradiate the 
flasks (ASAlaser, M6). 
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8. Cell count 
Five days after seeding, the PB-derived MSCs cultured in T25 flasks, with expansion and 
supplemented media, and treated with LLLT, reached 70% confluency.  
The old medium was removed and each flask was washed with PBS.  
2,5 ml of 0,25% Trypsin EDTA (Euroclone ECB3051D) were added, in order to detach the 
cells from the flask, following the procedure descripted at point 3.  
Then, cells were collected from each flask and counted in a Burker chamber. Alive and dead 
cells were distinguished by the use of Trypan Blue staining (Sigma B-7021). In fact, Trypan 
blue goes inside the cytoplasm of damaged cells and allow to establish the effects, of each 
treatment, on cell proliferation and viability.  
 
 
 
 
9. Cell freezing 
After cell count, 5x106 cells were collected from each flask and frozen at -80 °C, in order to 
stop cell proliferation and differentiation. The freezing medium was prepared with 90% 
expansion medium and 10% Dimethyl sulfoxide (DMSO). DMSO is a cryoprotective agent, 
which allows slow cooling rate and reduces ice crystal formation that can cause cell damage 
and death.  
Once the samples, containing the PB-derived MSCs, cultured in several media conditions and 
treated with LLLT, were frozen, they were shipped to the department of Comparative 
Biomedicine and Food Science of the University of Padua for consecutive analysis.  
 
 
Figure 4: Appearance of MSCs when stained with 
trypan blue, in a burker chamber. 
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10. RNA isolation 
The RNA of the PB-derived MSCs was isolated, in order to evaluate the effects of GFs alone, 
or in combination with LLLT, on mRNA expression of genes involved for tenogenic 
differentiation.  
In order to perform total RNA extraction, the samples were de-frozen and centrifuged at 800 
rpm for 5 minutes. The supernatant containing the freezing medium was eliminated, while the 
pellet containing the PB-derived MSCs, was suspended in 1 ml of TRIzol reagent (Life 
Technologies). Trizol is a substance, which cause cell lysis and nuclear-protein complexes 
dissociation. The samples were incubated for 5 min, at RT, and after this period of time, the 
RNA was in solution with other organic molecules.  
In order to isolate RNA, 0,2 ml of Chloroform (Sigma) were added. The solution was shuffled 
for 15 seconds and further incubated for 5 min at RT. Then, it was centrifuged at 12000g, for 
15 min, at 4 °C, and after this passage, it was possible to distinguish a pellet, containing 
proteins and lipids, and interphase containing DNA molecules, and the upper phase 
containing the RNA.  
The upper phase was collected and 0,5 ml of Isopropanol (Sigma) were added, in order to 
induce RNA precipitation. The samples were incubated for 10 min and then centrifuged at 
1200g for 10 min. 
At this point, the supernatant was eliminated and the pellet, containing the RNA of the MSCs, 
was re-suspended in 1 ml of Ethanol 70% (Sigma). Ethanol is important to wash RNA from 
isopropanol. The solution was centrifuged twice, at 7500g, for 5 min, and the supernatant 
gently removed from the pellet containing the purified RNA.  
The samples were left for 1 hour at RT, in order to allow ethanol evaporation.  
Finally, the total RNA was quantified. The pellet was re-suspended in 20 μl of distillate water 
and RNA quantified on a Nanodrop (Thermo Scientific) spectrophotometer. 
 
 
11. cDNA retro-transcription 
In order to perform real-time PCR, a complementary DNA (cDNA) was synthetized, starting 
from isolated mRNA of the PB-derived MSCs.  
At the beginning, the RNA was purified from DNA residues, which could be present from the 
isolation process. Hence, from each sample, 2 μg of RNA were added to 1 μl of Buffer 10x 
(Life technologies), 1 μl of DNase (Life technologies) and the necessary amount of distilled 
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water to obtain 10 μl in total. Buffer 10x contains Mg2+ ions, which allows DNase to work 
correctly and degrade DNA.  
The solution was incubated at RT and after 15 min, 1 μl of EDTA (Life technologies) was 
added, in order to chelate Mg2+ ions and stop DNase activity. Moreover, the solution was 
incubated at 65 °C for 10 min and then, for 1 min at 4 °C, with the purpose to create a thermal 
shock and stop definitely DNase activity.  
At this point, the single strands of purified mRNA were ready to be copied in cDNA.  
1μl of random primers and 1 μl of dNTP (Life technologies) were added to the solution, 
which was further incubated for 1 min at 65 °C and 1 min at 4 °C. Afterwards, 1 μl of 
Superscript (Life technologies), 1 μl of RNase OUT (Life technologies), 2 μl of DTT (Life 
technologies), and 4 μl of buffer 5x (Life technologies) were added to the samples. Hence, the 
solution was incubated for 10 min at RT and then, for 50 min at 42 °C. In this phase, 
Superscript (Reverse Transcriptase) synthetises the cDNA, starting from primers and then, it 
creates the helix using the four mixed deoxy-nucleotides (dNTP). Buffer 5x is important to 
allow superscript works correctly. RNase Out is a RNase inhibitor, which protects RNA from 
degradation and DTT (Dithiothreitol) works protecting RNase OUT from oxidation, because 
it is a reducing agent.  
Since Superscript creates strands of cDNA, which are still linked to the original mRNA, the 
samples were incubated for 15 at 70 °C. This is the last passage for cDNA retro-transcription, 
but it is important to destroy the single strands of RNA, in order to obtain purified cDNA, 
which can be used for real time-PCR.  
 
 
12. Real time-PCR 
Real time-PCR (or Real time-Polymerase chain reaction) was performed on purified cDNA, 
after the treatment with several combinations of GFs and LLLT.  
Real time-PCR is a laboratory technique of molecular biology, which allows the amplification 
and accumulation of cDNA in vitro and thus, the contemporary quantification of selected 
genes expression. In order to evaluate the effects of GFs and LLLT for tenogenic 
differentiation of PB-derived MSCs, the following genes were tested: Early growth response 
protein-1 (EGR1), Tenascin C (TNC) and Decorin (DCN). Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as housekeeping gene, with the purpose to obtain a 
relative quantification of the target genes.  
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Each sample was tested in triplicate. Untreated MSCs were used as calibrator sample and 
water as negative control. Real time-PCR was performed using the ABI 7500 Real Time-PCR 
system (Applied Biosystem), constituted of a thermocycler for a 96-well plate.  
In order to test all samples, eight 96-well plates were arranged. For each well, a total volume 
of 30 μl was added. The solution was prepared as follow: 15 μl of Buffer (Life technologies), 
10,2 μl of distilled water, 0,9 μl of primer Forward (diluted 1:10), 0,9 μl of primer Reverse 
(diluted 1:10), 3μl of cDNA (diluted 1:10) or 3 μl of distilled water for negative control.  
PCR primers were designed using Primer Express 3.0 software (Applied Biosystem). Forward 
and Reverse sequences are shown in Table 3.  
 
Table 3: Primers used for the quantitative Real time-PCR analysis 
Gene 5’ Forward primer 3’ 5’ Reverse primer 3’ 
GAPDH GCATCGTGGAGGGACTCA GCCACATCTTCCCAGAGG 
EGR1 CGGACATGACAACAACCTTTTC CCTTTGCCCTTTCCTTTAGCA 
DCN GAGAGCTGCGTGTCCATGAG AGTGGGTTGGTGCCAAGTTC 
TNC CATCCACCATCATCCAGGAGTT TGGCAAACACACGGATGAA 
 
The possibility for Real time-PCR to detect and quantify the amplification of cDNA, is due to 
SYBR green, a fluorescent molecule included in the buffer. SYBR green is a DNA-binding 
dyes and it yields a proportional increase in the amount of amplified DNA and fluorescence. 
The cycle number, in which enough amplified product determines a detectable fluorescent 
signal is called Ct. 
A 2-ΔΔCt method was used to analyse the data and determine the relative expression of the 
target genes to GAPDH and calibrator sample. 
The average number of Ct, for each gene and treatment, was normalized to Ct expression of 
GAPDH as follow:  
 ΔCt (test) = Ct (target genes) – Ct (GAPDH) 
 ΔCt (calibrator) = Ct (target calibrator) – Ct (GAPDH) 
 
Finally, the relative expression of target genes was normalized to calibrator as follow:  
 ΔΔCt= ΔCt (test) – ΔCt (calibrator) 
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13. Statistical analysis 
Normally distributed data were expressed as the mean ± standard deviation. Normality of the 
data was confirmed using the Kolmogorov-Smirnov test (α=5%). Statistical analysis was 
performed using the paired Student t test (SPSS software, version 11.0, SPSS, IBM). The 
level of statistical significance was set a P ≤ 0.05 for all analyses. 
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RESULTS 
 
1. Flow cytometry analysis of isolated PB-derived MSCs 
The cellular identification of the putative PB-derived MSCs was performed by using flow 
cytometry. Each sample, cultured in expansion medium, was tested at passage 5 (Figure 1A) 
and passage 10 (Figure 1B). The results showed a uniform positivity for stem cell markers 
CD29, CD44, CD90 and negativity for blood cell markers CD45, MHC II, Mo/Ma, at both 
passages.  
Control isotypes were tested for each marker, in order to define the threshold.  
The relative expression of positivity and negativity, for each CD tested, for each horse, is 
shown in table 1. 
These results indicated a successful isolation of MSCs from peripheral blood of four healthy 
horses, thus increasing the validity of consecutive analysis. 
 
  #1 #2 #3 #4 Average ± SD 
  P5 P10 P5 P10 P5 P10 P5 P10 P5 P10 
CD44 87.8 99.3 98.4 99.8 89.7 99.7 92.2 98.5 92.0±4.0 99.3±0.5 
CD90 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0±0.0 100.0±0.0 
CD29 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0±0.0 100.0±0.0 
Mo/Ma 0.8 4.8 0.3 0.6 0.9 0.0 1.1 0.1 0.8±0.3 1.4±2.0 
MHCII 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0±0.0 0.0±0.0 
CD45 2.2 0.7 0.8 1.2 13 1.3 2.4 1.6 1.7±0.6 1.2±0.3 
 
Table 1: The table shows the relative expression of the CDs tested, for each sample, at P5 and P10 and 
the average ± standard deviation (SD). Samples show a uniform positivity for antibodies against stem 
cell markers CD29, CD44, CD90, and negativity for blood cell markers CD45, MHC II and Mo/Ma.  
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Figure 1: The histograms show the relative number of cells versus mean fluorescence intensity. 
Samples were tested at P5 (A) and P10 (B) and at both passages, showed a positivity for stem cell 
markers CD29, CD44, CD90 (in dark blue), and negativity for blood cell markers CD45, MHC II 
and Mo/Ma (in red).  
 
 
 
 
HORSE SAMPLE 
A 
B 
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2. Population doubling time of isolated PB-derived MSCs 
Population doubling time (PDT) was calculated, in days, for each sample, from passage 1 to  
10 (P1→10), in order to determine the growth efficiency and proliferation rate of the PB-
derived MSCs, cultured in expansion medium.  
After an initial lag phase, MSCs divided rapidly at all further passages tested. PDT was 
relatively constant, starting from P3 to P10 (P3→10) (Figure 2). 
 
 
Figure 2: Population dubling time was calculated from P1 to P10 of  PB-derived MSC. The graphic 
shows the average cell kinetics of four horses. Error bars indicate ± standard deviation. 
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3. Cell proliferation and viability of PB-derived MSCs treated with GFs 
and LLLT 
Figure 3 shows the average number ± standard deviation (SD) of alive and dead cells, which 
were counted at the end of each treatment with GFs and LLLT. It is shown that only the 
combination of FGF + TGF influenced cell proliferation, causing a significant decrease in cell 
number (p ≤ 0,05), in both irradiated and non-irradiated flasks. On the other hand, the addition 
of FGF, FGF + IGF, or FGF + EGF, with and without LLLT, did not modify cell growth, 
compared to control.  
All treatments showed the same cytotoxicity, which was rather enhanced than control 
medium, but not significantly high in none of the treatments.  
These data indicate that TGF was the only growth factor able to cause a significant decrease 
in cell proliferation. However, it did not affect cell mortality, which remained rather constant 
among treatments.  
 
 
 
Figure 3: The histogram shows the average ± SD number of cells counted after each treatment. The 
number of alive cells is represented by light grey bars, whereas, the number of dead cells is indicated 
by dark grey bars. The treatments did not modify cell mortality but influenced cell proliferation, which 
was significantly decreased when cells were cultured with TGF, with and without LLLT. 
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4. mRNA expression of EGR1, TNC and DCN 
In order to evaluate the best culture conditions for tenogenic differentiation, the relative gene 
expression of Early Growth Response Protein-1 (EGR1), Tenascin C (TNC) and Decorin 
(DCN) was measured by Real time-PCR, since they are all crucial genes involved in 
tenogenesis.  
The relative expression of EGR1 and DCN increased significantly in presence of FGF + TGF, 
both with and without LLLT.  
The relative expression of TNC increased when PB-derived MSCs were cultured in 
supplemented media with FGF +TGF, but the increase became statistically relevant (P ≤ 0,05) 
only when this arrangement was combined with LLLT (Figure 4).  
The addition of FGF alone, or in combination with IGF, or EGF, did not show significant 
increasing trends in comparison with the control (Exp). Cells treated with LLLT alone, or in 
combination with GFs, did not show a significant increase in the expression of target genes, 
except for TNC, which was up-regulated only when cells were cultured with FGF + TGF and 
treated with LLLT.  
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Figure 4: The histograms show the average mRNA expression of EGR1, TNC and DCN in PB-
derived MSCs after five days of medium conditioning and four days of LLLT. The relative expression 
of the target genes was measured by Real time-PCR, GAPDH was used as housekeeping gene and 
cells cultured in expansion medium (Exp) served as calibrator. Asterisks indicate statistical treatments.  
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DISCUSSION 
Tendon injuries are one of the most common orthopaedic problems in equine athletes. 
Besides, tendon anatomical characteristics are essential to confer the appropriate stiffness and 
elasticity, the avascularized nature, the hypocellularity, and the low metabolic rate predispose 
tendons to slow healing, after injury.  
Tendon injury may result from an acute trauma, or more often, from chronic overstrain. 
Several predisposing factors have been investigated in the development of tendinopathies, but 
it has been recorded that during gallop, the equine flexor compartment works close to its 
physiological limit (Stephens et al. 1989).  
Since tendons heal slowly, with the formation of scar tissue, which is always mechanically 
inferior, there is a substantial loss in strength, elasticity, and a reduced athletic performance, 
with a high incidence of relapses.  
In fact, the higher amount of collagen type III tends to produce smaller and less organized 
fibrils, which will provide only a structural (repair), but not functional (regeneration) 
recovery.  
Many medical and surgical therapies have been advocated in the treatment of equine tendon 
injuries, but without significant effects. Nowadays, the improvement of regenerative therapies 
has shown promising results with the application of stem cell-based therapies, growth factors 
(GFs) and low-level laser therapy (LLLT). 
In this purpose, the hypothesis of the present study was to define, if a specific mixture of GFs, 
in combination with LLLT, could increase MSCs differentiation towards the tenogenic fate in 
vitro. In fact, it has been shown that the clinical administration of previously induced MSCs, 
can improve tendon regeneration and facilitate a more efficient recovery after injury 
(Pietschmann et al. 2013). However, the exact modus operandi of SCs is not completely 
understood and more in vitro studies must be performed, in order to better understand the 
correlation between MSCs and their niche.  
MSCs were isolated from the peripheral blood of four healthy horses. It has been shown that 
peripheral blood is an excellent source of MSCs, in fact, samples can be easily taken in a 
sterile manner, at the time of injury. Therefore, peripheral blood is a high accessible source of 
MSCs for regenerative therapies, which is overall preferred than more invasive sources such 
as, bone marrow or adipose tissue (Spaas et al. 2013). 
For quality control purposes, flow cytometry was performed on the putative PB-derived 
MSCs at passage 5 (P5) and 10 (P10).  Flow cytometry works by detecting the fluorescent 
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signal delivered by the link between marked antibodies and glycoproteins, which are 
expressed on the surface of cell membrane, called Cluster of differentiation (CD). It is 
important to achieve the immunophenotypical characterization of the putative MSCs, in order 
to identify them objectively after isolation (Dominici et al. 2006). Passage 5 and 10 were 
chosen to generate multiple samples, because of insufficient cell yield at earlier stages. MSCs 
showed a positive expression for the stem cells markers CD 29, CD 44, CD90 and a negative 
expression for the blood cells markers CD45, MHC II, Mo/Ma, at both passages. These date 
confirmed a successful isolation of MSCs from peripheral blood and showed that cells did not 
lose their potential and self-renewal properties, by the expression of stem cell markers, in both 
passages tested. 
Moreover, population doubling time (PDT) was calculated from P1 to P10, for each cell culture 
obtained from the four horses. PDT is an important parameter, which measures cell growth 
kinetics. It represents the time, which cells require to double in number. PDT is directly 
correlated with MSCs health and senescence, since it increases when cells start to 
differentiate, losing their potential. After an initial lag phase, PDT was relatively constant 
among passages, indicating that cells maintained their proliferative potential until P10.  
When MSCs reached P5, they were seeded in T25 flasks and cultured in five different media 
conditions. More than expansion medium (Exp), which served as negative control, basic 
Fibroblast growth factor (FGF), Transforming growth factor-β3 (TGF), Insulin-like growth 
factor-1 (IGF) and Epidermal growth factor (EGF), were added to Exp, creating the following 
combinations: Exp, FGF, FGF + TGF, FGF + IGF, FGF + EGF.  
All these GFs were added at the same concentrations (10 ng/ml), in order to standardize the 
effects. Each combination was tested in duplicate, for each horse. 
Since several studies have confirmed the key role of FGF in tendon healing, cell proliferation 
and differentiation (Cai et al. 2013; Chan et al. 2000; Chang et al. 1998; Hankemeier et al. 
2005), FGF was first tested alone, and then in combination with TGF, IGF and EGF. The 
purpose was to evaluate the synergistic effect of FGF and other GFs, which are involved in 
tendon healing and tenogenic differentiation. 
In order to allow cell attachment and GFs conditioning, the first irradiation was performed 
after 24 hours from the seeding in T25 flasks. The flasks were divided in two equal groups 
and only one (Group 2) was submitted to LLLT. An energy density of 5J/cm2 was chosen, 
because several in vitro studies support the hypothesis that 5J/cm2 is the optimal fluence to 
apply, in order to enhance cell proliferation and differentiation (Hou et al. 2008; de Villiers et 
al. 2011). On the other hand, a recent in vivo study, conducted on collagenase-induced 
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tendinitis in sheep, showed that a dose of 5J/cm2 was excessive for the treatment of acute 
tendinitis and the application of lower doses was recommended (Iacopetti et al. 2015). 
However, it is important to precise that in vivo studies include many variables, therefore the 
results could be really different among in vivo and in vitro studies.  
After five days of media conditioning and four days of LLLT, the cells were counted, in order 
to evaluate the effects of the treatments on cell proliferation and viability. 
The results showed that FGF, alone, was not able to increase significantly cell number, 
besides it is reported that FGF as a potent stimulator of cell proliferation (Cai et al. 2013; 
Chan et al. 2000; Chang et al. 1998; Hankemeier et al. 2005; Molloy et al. 2003). In fact, in 
both FGF and FGF + LLLT treatments, the total number of cells was not increased, compared 
to control, besides an appropriate dosage of FGF was used. It is known that an inappropriate 
amount of FGF may reduce its effects, but in this case, a concentration of 10 ng/ml was used, 
as reported by other studies, which have successfully tested it to increase MSCs growth and 
differentiation (Hagmann et al. 2013).  
The combined addition of FGF + IGF and FGF + EGF caused a slight increase of cell 
number, in both irradiated and non-irradiated flasks, but the proliferation did not increase 
significantly. Beside the results were not significant, an addictive effect of IGF and EGF with 
FGF is supposed. In fact, both IGF and EGF are powerful mitogen factors, which increase 
especially after injury. In fact, IGF and EGF play a key role during the inflammatory phases, 
promoting cell proliferation and migration. In this regard, it is supposed that the increase 
observed after their addition is mainly due to these growth factors than FGF, which alone did 
not affect cell growth compared to control medium (Gonçalves et al. 2013; Molloy et al. 
2003).  
Only the combination of FGF + TGF caused a significant drop in cell number, confirming the 
anti-proliferative effect of TGF, which works through the activation of cyclin-dependent 
kinase pathway (Klein et al. 2002).  
On the other hand, TGF did not influence cell death, which remained fairly constant among 
treatments. Since the addition of TGF stopped cell proliferation, the MSCs differentiation 
towards the tenogenic fate is supposed and this result is even more presumable, since cell 
death remained constant among treatments. In fact, several studies confirmed the ability of 
TGF to increase the mRNA expression of TNC, Collagen type I, collagen type III, COMP, 
tenomodulin, and thrombospondin, which are all components of the extracellular matrix 
(ECM) of tendon tissue (Barsby et al. 2014; Dowling et al. 2000; Klein et al. 2002). In 
addition, it is important to underline that TGF significantly decreased cell number in both 
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non-irradiated and irradiated flasks, despite several studies demonstrated the proliferative 
effect of LLLT, when it is applied with a fluence of 5J/cm2. It has been shown that LLLT can 
enhance cell differentiation as well, when cells are cultured in appropriate inducing medium 
(de Villiers et al. 2011; Hou et al. 2008). In this regard, it is supposed that the application of a 
LLLT in vitro is useful to increases the effects of the medium where cells are cultured, but it 
is not able to produce conflicting effects. Moreover, the application of higher energy doses 
would not be useful to increase cell proliferation, because the cell damage would be 
excessive, thus increasing cell death (Hawkins and Abrahamse 2006). 
After cell count, the MSCs were frozen and shipped to the department of Comparative 
Biomedicine and Food Science of the University of Padua, where Real time-PCR was 
performed.  
For the first time, the relative expression of the following genes was evaluated in equine 
MSCs: Early Growth Response Protein-1 (EGR1), Tenascin C (TNC) and Decorin (DCN), 
since they are all crucial genes involved during tendon development. 
The results showed that the combination FGF + TGF increased significantly the relative 
expression of EGR1 and DCN, in both irradiated and non-irradiated flasks, whereas only the 
combination FGF + TGF + LLLT was able to increase statistically the amount of TNC. Since 
the same treatments caused a significant decrease in cell proliferation, without affecting cell 
death, it is supposed that the MSCs started to differentiate towards the tenogenic fate. In fact, 
EGR1 is one of the first transcription factors involved in the tenogenic cascade (Lejard et al. 
2011) and DCN is involved in tendon development as well. DCN participates in the 
organization of tendon hierarchical structure, by coordinating fibrillogenesis (Zhang et al. 
2006). Since DCN is a biological ligand for the EGF receptor, we would expect a significant 
increase of its relative expression in the following combinations: FGF + EGF or FGF + EGF 
+ LLLT. In fact, the link with the EGF receptor triggers a signalling cascade that leads to the 
activation of the MAPK pathway, which regulates cell proliferation and differentiation (Iozzo 
et al. 1999). However, the results showed that the relative expression of DCN was comparable 
to control medium, suggesting that the addition of EGF is not recommended to induce the 
tenogenic differentiation of MSCs.   
The only combination, which increased statistically the relative expression of TNC was FGF 
+ TGF + LLLT. TNC is a ECM glycoprotein, which plays a key role in collagen fibril 
organization, maintaining the interface between fibrils and the adjacent structures (Riley et al. 
1996). TNC is normally up-regulated during embryogenesis, but it has been shown that its 
expression increases also in those areas subjected to mechanical stress. Moreover, TNC 
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expression may rise when cells are cultured with FGF or TGF.  Pearson et al. (1988) showed 
that TGF may increase 4 times TNC secretion in chick embryo fibroblasts, whereas in another 
study FGF and TGF were first tested alone, and then in combination, resulting in addictive 
effect when used together (Tucker et al. 1993). Since in our study TCN increases only when 
the flasks supplemented with FGF and TGF were irradiated, it is supposed an enhancing 
effect by the LLLT. In fact, the application of an energy laser density of 5J/cm2 was showed 
to be optimal to increase cell proliferation, but differentiation was enhanced only when cells 
were cultured in appropriate inducing medium (de Villiers et al. 2011; Hou et al. 2008). Since 
LLLT alone is not able to induce cell differentiation, it is supposed that the irradiation of the 
flasks helped to increase the TNC content, to the point that it resulted statistically relevant. In 
fact, the cells were treated for only five days with supplemented media and four days with 
LLLT. In this regard, it is supposed that cells cultured with FGF and TGF were only induced 
towards the tenogenic line, but they did not differentiate in mature tenocytes. In fact, the 
relative expression of genes, which are normally up-regulated in tendon development is 
increased. In order to better define, if the supplementation of expansion medium with 10 
ng/ml of FGF and TGF could be recommended to induce the tenogenic differentiation of 
MSCs, it would be interesting to culture the PB-derived MSCs for a longer period in this 
medium, with and without LLLT, and then evaluate the relative expression of genes, which 
are normally expressed in mature tendon such as, Collagen type I and cartilage oligomeric 
matrix proteins (COMP). 
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CONCLUSIONS 
The effects of growth factors (GFs) on cell cultures are influenced by numerous variables 
such as: MSCs source, GF concentration, timing of incubation and GFs combinations. 
We consider that the present study might provide a starting point for the development of an 
efficient approach for tenogenic induction of equine peripheral blood (PB)-derived 
mesenchymal stem cells (MSCs). In fact, the supplementation of expansion medium with 10 
ng/ml of FGF and TGF, surely accelerate the differentiation of PB-derived MSCs towards the 
tenogenic fate. Overall, more in vitro and in vivo studies have to be performed, in order to 
better understand the correlation between MSCs and their niche. The possibility to induce 
MSCs differentiation in vitro, through the application of standard protocols of differentiation, 
would enhance the development of regenerative therapies. In the future, we do hope that it 
will be possible to apply MSCs routinely, not only for the treatment of tendinopathies, but 
also to restore complex structure of damaged tissues and organs.  
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